Cerebrospinal fluid from patients with subarachnoid haemorrhage and vasospasm enhances endothelin contraction in rat cerebral arteries. by Assenzio, B et al.
RESEARCH ARTICLE
Cerebrospinal Fluid from Patients with
Subarachnoid Haemorrhage and Vasospasm
Enhances Endothelin Contraction in Rat
Cerebral Arteries
Barbara Assenzio1, Erica L. Martin1, Edgaras Stankevicius2, Federica Civiletti1,
Marco Fontanella3, Riccardo Boccaletti3, Maurizio Berardino1, AnnaTeresa Mazzeo1,
Alessandro Ducati3, Ulf Simonsen4, Luciana Mascia1*
1 Department of Anesthesia and Intensive Care, Azienda Ospedaliera Città della salute e della scienza di
Torino, University of Turin, Turin, Italy, 2 Institute of Physiology and Pharmacology, Medical Academy,
Lithuanian University of Health Sciences, Kaunas, Lithuania, 3 Division of Neurosurgery, Department of
Neuroscience, Azienda Ospedaliera Città della salute e della scienza di Torino, University of Turin, Turin,
Italy, 4 Department of Biomedicine, Pulmonary and Cardiovascular Pharmacology, University of Aarhus,
Aarhus, Denmark
* luciana.mascia@unito.it
Abstract
Introduction
Previous studies have suggested that cerebrospinal fluid from patients with subarachnoid
hemorrhage (SAH) leads to pronounced vasoconstriction in isolated arteries. We hypothe-
sized that only cerebrospinal fluid from SAH patients with vasospasm would produce an en-
hanced contractile response to endothelin-1 in rat cerebral arteries, involving both
endothelin ETA and ETB receptors.
Methods
Intact rat basilar arteries were incubated for 24 hours with cerebrospinal fluid from 1) SAH
patients with vasospasm, 2) SAH patients without vasospasm, and 3) control patients. Arte-
rial segments with and without endothelium were mounted in myographs and concentra-
tion-response curves for endothelin-1 were constructed in the absence and presence of
selective and combined ETA and ETB receptor antagonists. Endothelin concentrations in
culture medium and receptor expression were measured.
Results
Compared to the other groups, the following was observed in arteries exposed to cerebro-
spinal fluid from patients with vasospasm: 1) larger contractions at lower endothelin concen-
trations (p<0.05); 2) the increased endothelin contraction was absent in arteries without
endothelium; 3) higher levels of endothelin secretion in the culture medium (p<0.05); 4)
there was expression of ETA receptors and new expression of ETB receptors was apparent;
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5) reduction in the enhanced response to endothelin after ETB blockade in the low range
and after ETA blockade in the high range of endothelin concentrations; 6) after combined
ETA and ETB blockade a complete inhibition of endothelin contraction was observed.
Conclusions
Our experimental findings showed that in intact rat basilar arteries exposed to cerebrospinal
fluid from patients with vasospasm endothelin contraction was enhanced in an endotheli-
um-dependent manner and was blocked by combined ETA and ETB receptor antagonism.
Therefore we suggest that combined blockade of both receptors may play a role in counter-
acting vasospasm in patients with SAH.
Introduction
Cerebral vasospasm is one of the most serious complications following aneurysmal subarach-
noid hemorrhage (SAH) and is independently associated with poor outcome [1]. Endothelin-1
(ET-1) is thought to be of major importance for cerebral vasospasm [2,3]
In experimental models of SAH, increased sensitivity of cerebral arteries to ET-1 have been
invariably reported [4]; increased levels of ETA receptor mRNA have been inconsistently
demonstrated [5] [6,7]while increased levels of ETB mRNA have been unequivocally reported
[8–10] [11]. So far studies on endothelin-1 receptor regulation did not differentiate between
the two conditions of SAH with and without vasospasm [6,9,10,12]. Moreover, and in vitro
studies on the cerebral microvasculature have often been used to explain events observed in
conductive vessels[13]. Furthermore, although the cerebral endothelium is unique in terms of
growth and responsiveness to various vasoactive agonists, results obtained in non-cerebral en-
dothelial cells have been extrapolated to the brain vasculature[14,15].
The efficacy of selective receptor antagonists have been tested in experimental models of ce-
rebral vasospasm [5,16,17]. Several randomized clinical trials tested the efficacy of ETA selec-
tive blockade and found a reduction in angiographic vasospasm but no improvement in
measureable functional outcomes [18–22]. These results pose several questions: 1) the possibil-
ity that early brain injury occurring just after the hemorrhage may contribute to the poor out-
come; 2) a functional interaction between ETA and ETB receptors named “cross talk” may play
a role in the pathogenesis of SAH-induced vasospasm.
To overcome the above-mentioned methodological criticisms and to elucidate the function-
al interaction between the two receptors, we evaluated the upregulation of the endothelin sys-
tem of the targeted vessels by vasospasm, incubating intact and denuded conductive cerebral
vessels with CSF from SAH patients with a conclusive diagnosis of vasospasm obtained
by angiography.
We hypothesized that CSF from SAH patients who developed vasospasmwould produce an en-
hanced contractile response in intact rat cerebral arteries involving both ETA and ETB receptors.
Materials and Methods
Patient Selection
Ethical approval
The present study was conducted using CSF from patients with aneurysmal SAH confirmed by
CT scan and angiography admitted to ICU. CSF had been collected for an observational study
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in SAH patients at risk of developing vasospasm (NCT01686763). The institutional review
board (Comitato Etico Interaziendale A.O.U. San Giovanni Battista di Torino A.O. C.T.O./
Maria Adelaide di Torino) approved the study. If the patient was unable to give consent at
study entry, consent was delayed, and the family was informed of the study. Written permis-
sion for using collected data was thus obtained from the patient (if competent) or from the
family (in case of death or if the patient remained incompetent).
All the patients fulfilled the following inclusion criteria: 1) angiographic proof of aneurysm;
2) admission within 24 hours of the SAH; and 3) presence of an intraventricular catheter placed
either after admission or at the time of surgery. Patients were graded clinically according to the
World Federation of Neurological Surgeons (WFNS) scale and classified according to the CT
distribution of blood as described by the Fisher scale.
All patients underwent neurosurgical intervention or endovascular procedure to secure the
aneurysm within 2 days of admission. Neurological status was evaluated daily using the Glas-
gow Coma Scale (GCS), transcranial Doppler of the middle cerebral arteries was performed
daily until day 14 and patients were treated according to the guidelines [1].
On day 7 post-SAH, a second angiogram was routinely performed and the patients were
then classified as having: 1) angiographic vasospasm (AV) if the angiogram showed 25% or
more reduction from baseline caliber without any clinical deterioration; 2) clinical vasospasm
(CV) if a reduction in the angiographic caliber>50% of the middle cerebral artery (MCA) was
accompanied by controlateral weakness to or global neurological deterioration (two points re-
duction in GCS) occurring later than day 3 for anterior or diffuse vasospasm; 3) patients with-
out vasospasm (NV) if there was reduction lower than 25% in the angiographic caliber [23]
[24].
To test the hypothesis of the present study samples of CSF from patients with the most se-
vere vasospasm (clinical vasospasm CV) and from those without vasospasm (no vasospasm
NV) were included. As negative control a group of patients with normal pressure hydrocepha-
lus (NPI) and normal GCS undergoing lumbar drainage for the diagnosis of NPI was included
[25]. In SAH patients CSF was collected daily until day 7, with the samples collected on days
4–5 used for the present study. CSF was drawn into tubes containing EDTA from the intraven-
tricular catheter and collected by ventricular drainage from hydrocephalus patients. Tubes
were kept and transported in ice. All CSF samples were centrifuged at 1700g for 15 min at 4°C
to remove intact cells and cellular debris, following which the supernatant was frozen at −80°C.
Functional study of the Ex VivoModel of SAH-induced Vasospasm
Isolated rat basilar arteries were obtained from male Wistar rats (350–400g) (Charles River
Laboratories, Calco, Italy). Rats were group-housed, had free access to standard chow and
water in a controlled facility providing a 12-hour light/dark cycle, and were kept according to
institutional animal welfare guidelines and legislation, submitted and approved by the local
Animal Ethics Committee (Comitato di Bioetica dell’Ateneo dell’Università degli Studi di To-
rino) and all efforts were made to minimize suffering. Rats were sacrificed by carbon dioxide
overdose followed by cervical dislocation and the cerebral basilar artery was isolated using a
stereomicroscope and immersed in ice-cold physiological salt solution (PSS) (CaCl2 2H2O 2.5
mmol/L, NaCl 119 mmol/L, KCl 4.69 mmol/L, glucose 5.5 mmol/L, MgSO4 7H2O 1.17nmol/L,
NaHCO3 25 mmol/L, KH2PO4 1.18 mmol/L and ethylenediaminetetraacetic (EDTA) 0.03
mmol/L). Segments of approximately 2 mm in length were incubated with 5% human CSF (v/
v) obtained from ventricular drainage of the patients included in the study. Incubation lasted
24 hours at 37°C with 5% CO2 in O2 in Dulbecco’s modified Eagle’s medium (DMEM). The
culture medium was then collected and frozen at −80°C for analysis of ET-1 concentrations.
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Following incubation with human CSF, isolated rat basilar arteries were mounted on 40 μm
tungsten wires in a small vessel myograph (D.M.T., Aarhus, Denmark) for isometric force re-
cording [26]. Measurements were recorded using the ICU-Lab software program (KleisTEK
Advanced Electronic Systems; Bari, Italy). The vessels were allowed to equilibrate for about 30
min in PSS, which was continuously aerated with oxygen enriched with 5% CO2 to maintain a
pH of 7.4. The relation between resting wall tension and internal circumference was deter-
mined, and the internal circumference, L100, corresponding to a transmural pressure of 100
mmHg for a relaxed vessel in situ was calculated. The vessels were set to the internal circumfer-
ence L1, given by L1 = 0.9L100. The effective internal lumen diameter was determined as l1 = L1/
π, and was 306±41 mm (mean±SD, N = 106) and 303±38 μm (mean±SD, N = 20) in vessels
with and without endothelium respectively.
After a 30 min period to stabilize vessel tone, the contractile capacity was determined by ex-
posing the vessels to an isotonic solution containing 123 mmol/l of K+ (KCl 123.70 mmol/L,
MgSO4 7H2O 1.17 nmol/L, KH2PO4 1.18 mmol/L, CaCl2 2H2O 2.5 mmol/L, NaHCO3 25
mmol/L, EDTA 0.03 mmol/L, glucose 5.5 mmol/L), obtained by equimolar change of NaCl for
KCl in PSS. Only vessels responding by contraction corresponding to a pressure above 13.3
kPa to potassium were included in the study. The presence of an intact endothelium was
checked by contracting the vessel using serotonin (5-HT, 10−5 mol/L, Sigma-Aldrich, Milan,
Italy) and subsequently exposing the segments to histamine (10−5 mol/L, Sigma-Aldrich,
Milan, Italy) to stimulate endothelium-dependent relaxation. Confirmation of the presence of
endothelium was determined by a relaxation>50% (E+). In a separate set of experiments the
endothelial cell layer was mechanically removed by gentle rubbing the intimal surface with a
human hair (E−). After endothelial cells removal the contractility of the vessels was tested by
adding serotonin.
We did not find any difference in serotonin response between groups with or without endo-
thelial cells. The response to 5-HT was 1.59±0.56 (n = 6) and 1.43±0.48 mN/mm (n = 8), re-
spectively, in vessels with and without endothelium exposed to CSF from the Control group,
and 1.59±0.56 (n = 6) and 1.34±0.44 mN/mm (n = 6) in vessels with and without endothelium
exposed to CSF from the Non-Vasospasm group, and 1.79±0.50 (n = 6) and 1.74±0.43 mN/
mm (n = 6) in vessels with and without endothelium exposed to CSF from the
Vasospasm group.
In a separate set of vessels, following exposure of the isolated basilar arteries to 5% human
CSF, vessels were incubated with specific antagonists to 1) ETA (BQ-123, 1×10
−5 mol/L,
Sigma-Aldrich, Milan, Italy), 2) ETB (BQ-788, 1×10
−6 mol/L, Sigma-Aldrich S.r.l, Milan, Italy)
3) both ETA and ETB (BQ-123 and BQ-788) 4) vehicle control for 30 min prior to performing
concentration-response curves by cumulative application of ET-1.
Enzyme-linked Immunosorbent Assay (ELISA)
ET-1 concentrations in CSF and in culture medium obtained before and after the incubation of
the arteries were determined by ELISA (Human ET-1 (1–21), with sensitivity<0.05 pg/ml;
Biomedica Diagnostics Inc, Vienna, Austria).
Immunofluorescence
After the 24-hour incubation in CSF, basilar arteries were embedded in Tissue-Tek (Sakura,
Zoeterwoude, NL) and frozen in liquid nitrogen. Cross-sections of the embedded vessels were
then cut into 20 μm sections. The first antibodies used were rabbit anti-rat ETA (AB3260, Che-
micon International, Vimodrone, Italy), diluted 1:200, and rabbit anti-rat ETB (AB3284,
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Chemicon International, Vimodrone, Italy), diluted 1:200 or irrelevant isotype contol antibody.
All dilutions were performed in PBS with 5% bovine serum albumin (Sigma-Aldrich., Milan,
Italy). The second antibodies used were goat anti-rabbit Alexafluor 488 conjugated (A11070,
Invitrogen, San Giuliano Milanese, Italy), diluted 1:500 in PBS with 5% bovine serum albumin.
The antibodies were detected at the appropriate wavelength using confocal microscopy (Leica
TCS SP2, Mannheim, Germany). As control, only secondary antibodies were used. All samples
were scanned in the same parameter setting throughout each series of immunoincubation, in-
cluding same size of pin hole, gain level, black level, and laser power. The quantification analy-
sis of immunoreactivity was carried out on single confocal image using Leica confocal software.
As first step, background fluorescence was estimated by analysing the distribution of the pixel
intensities in the image areas that did not contain any immunoreactive objects (the background
threshold). The background was subtracted by setting the baseline of pixel intensities to the
background value; autofluorescence was then subtracted. In the next step, an arbitrarily out-
lined polygon, which covered the vessel-occupied and imaged area, was chosen. In the polygon
area, the relative area of immunolabelled pixels with an intensity value above the background
was calculated. The fluorescence in five different areas on each artery was measured and the
mean value for each vessel was used.
Statistical Analysis
Data analysis
All recorded data were analyzed and expressed as tension (mN/mm) developed by the artery,
defined as the force induced divided by two times the vessel length because we did not find any
differences on potassium induced contraction among groups. In a given experiment, Emax de-
notes the maximal contractile response, and pEC50 denotes the negative logarithm of the con-
centration that elicits one-half of the maximal response. For biphasic responses, Emax1 and
pEC50(1) were used to describe the high-affinity phase and Emax2 and pEC50(2) were used to de-
scribe the low-affinity phase of the concentration-response curves.
Continuous data are presented as mean ± standard error of the mean. Data normally dis-
tributed were analyzed by one-way or two-way ANOVA, followed by a Student’s t-test or
Tukey-Kramer post-hoc test where appropriate, and data not normally distributed were ana-
lyzed by a non-parametric Kruskal-Wallis with Dunn’s post-hoc test. Differences were consid-
ered significant when the probability value was<0.05. Statistical analysis was performed using
SPSS-statistical software, version 17.0 (SPSS Inc. Chicago, IL).
Results
Inclusion criteria, demographic and clinical data of patients with subarachnoid hemorrhage in-
cluded in the present study are reported in Table 1. The control group consisted of six patients
(4 females, mean age 54±10) with diagnosed communicating hydrocephalus and normal GCS
undergoing lumbar drainage.
Functional Analysis
Rat basilar arteries incubated with CSF from Vasospasm patients developed greater contractile
forces at lower ET-1 concentrations compared to vessels incubated with Non-Vasospasm CSF,
as shown in the representative myograph trace (Fig. 1).
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Experiments in arteries with endothelium
In E+ vessels an enhanced concentration-dependent contractile response to ET-1 was present
in the Vasospasm group when compared with the Non-Vasospasm and Control groups at ET-
1 concentrations between 1×10−12.5 and 1×10−7 mol/L (p<0.05) (Fig. 2 upper panel). Interpo-
lation of the concentration-response curves showed a biphasic response in all three groups.
Analysis of the Emax and pEC50 for each phase showed that the Emax1, Emax2 and pEC50(2) were
significantly higher in the Vasospasm group compared to the Non-Vasospasm or Control
groups (Table 2).
Experiments in arteries without endothelium
In E− vessels all the three groups exhibited a similar biphasic response (Table 2). The enhanced
contractile response to ET-1 observed in arteries with endothelium and exposed to CSF from
patients with vasospasm was absent in arteries without endothelium (Fig. 2 lower panel).
ET-1 concentrations in CSF used for vessels incubation were 2.45 ±0.81 pg/ml in Non-Vaso-
spasm group and 2.63±1.31 pg/ml in Vasospasm group. After dilution, ET-1 concentrations in
the culture medium at the beginning of the incubation were undetectable in all groups (data
not shown), but ET-1 concentration after 24 hours incubation was significantly higher in the
Vasospasm (1.71± 0.4 pg/ml) compared to the Non-Vasospasm(0.82± 0.2 pg/ml) and Control
groups (0.91± 0.04 pg/ml) (p<0.05).
Endothelin Receptor Expression in the Ex VivoModel of SAH-induced
Vasospasm
There was a faint autofluorescence in the arterial segments examined by confocal microscopy.
When autofluorescence was subtracted ETA receptors were found to be constitutively express-
ed in the smooth muscle cell layer of arteries exposed to CSF from all three patient groups
(Fig. 3A). Semiquantitative immunofluorescence for ETB receptors revealed that the expression
apparently was markedly enhanced in the smooth muscle cell layer comparing arteries
Table 1. Demographic and clinical data of 17 patients studied.
SAH Non-Vasospasm (8) SAH Vasospasm (9)
Gender (M/F) 3/5 4/5
Age (years) 61 ± 11 57 ± 12
Aneurysm location (n)
MCA 2 4
A com 4 2
ICA 1 1
Basilar 1 1
WFNS grade I-II (n) 3 3
WFNS grade III-V (n) 5 6
clipping/coiling 7/1 8/1
GCS admission 11±3 11±3
Fisher grade 3 (n) 4 4
Fisher grade 4 (n) 4 5
Data expressed as mean ± SD or N; MCA = middle cerebral artery, ICA = internal carotid artery, A com =
anterior communicating WFNS = World federation of neurological surgeons, GCS = Glasgow Coma Scale
doi:10.1371/journal.pone.0116456.t001
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incubated with CSF from patients with Vasospasm than in those incubated with CSF from
Non-Vasospasm and Control patients (Fig. 3B) (260±9%; p<0.001, results not shown).
Effects of Selective and combined Endothelin Receptor Blockade
In a separate set of experiments, the ET-1 concentration-response curve was obtained with and
without blockade of the individual and combined ETA and ETB receptors (Table 3). In cerebral
arteries incubated with CSF from Non-Vasospasm group pretreatment with ETA antagonist
(BQ-123) reduced the contractile response for ET-1 concentrations between 1×10−11 to 1×10−8
mol/L; pretreatment with ETB antagonist (BQ-788) did not alter ET-1 induced contraction,
while pretreatment with both ETA and ETB antagonists abolished the contractile response for
ET-1 concentrations between 1×10−11.5 to 1×10−8 mol/L (Fig. 4, upper panel). In cerebral arter-
ies incubated with CSF from the Vasospasm group pretreatment with ETA antagonist (BQ-
123) significantly reduced the contractile response in the high range of ET-1 concentrations
Figure 1. Experimental myograph record of isolated rat basilar arteries incubated with 5% CSF from patients with SAHwith and without
vasospasm. The contractile force generated during exposure to increasing doses of ET-1 by Log (0.5 mol/L) every 5 min was higher at lower ET-1
concentrationsfor Vasospasm (bottom panel) compared toNon-Vasospasm (top panel).
doi:10.1371/journal.pone.0116456.g001
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(between 1×10−11.5 to 1×10−7.5 mol/L), pretreatment with ETB antagonist reduced the contrac-
tile response in the low range of ET-1 concentrations (between 1×10−14 to 1×10−12 mol/L),
while pretreatment with both ETA and ETB antagonists completely abolished the ET-1 induced
contraction (Fig. 4, lower panel).
Figure 2. Concentration-response curves elicited by ET-1 in isolated rat basilar arteries with
endothelium (E+) and without enodthelium (E−) following incubation with 5% human CSF fromControl
(n = 6), Non-Vasospasm (n = 6) and Vasospasm (n = 6) patients (upper panel) and fromControl (n = 8),
Non-Vasospasm (n = 6) and Vasospasm (n = 6) patients (lower panel). The response to ET-1 was
significantly increased in the Vasospasm group compared toControl andNon-Vasospasm groups only in
intact vessels. Significance by Kruskal Wallis with Dunn’s post-hoc test where *p<0.05 = Vasospasm versus
Control andNon-Vasospasm.
doi:10.1371/journal.pone.0116456.g002
Table 2. Contractile response to ET-1 in rat basilar arteries with (E+) and without (E−) endothelium following incubation with human CSF.
E+ E−
Non-Vasospasm Vasospasm Ctrl Non-Vasospasm Vasospasm
(n = 6) (n = 6) (n = 6) (n = 8) (n = 6) (n = 6)
Emax1 ± SEM(mN/mm) 1.04±0.13 0.86±0.11 2.10 ± 0.28* 0.81±0.08 0.83±0.15 0.92±0.07
Emax2 ± SEM(mN/mm) 2.27 ± 0.15 2.09±0.15 3.38 ± 0.12* 1.82±0.11 1.83±0.17 2.03±0.13
pEC50(1) ± SEM 12.13 ±0.50 12.33±0.44 13.01 ± 0.36 12.3±0.51 12.0±0.49 12.01±0.28
pEC50(2) ± SEM 9.19 ± 0.34 8.50±0.27 10.26 ± 0.37* 8.69±0.22 8.47±0.34 8.23±0.24
Values are expressed as mean ± SEM. Significance was determined by one-way ANOVA with Tukey-Kramer post-hoc where; ctrl = control
* p<0.05 = Vasospasm versus Control and Non-Vasospasm.
doi:10.1371/journal.pone.0116456.t002
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Discussion
This study for the first time clearly describes the functional response, protein expression, and
effects of selective and combined blockade of both ETA and ETB receptors in two well-defined
conditions: intact conductive cerebral vessels exposed to the biological effects of the hemor-
rhagic event (SAH without vasospasm) and vessels exposed to the combined biological effects
of SAH and vasospasm. When CSF from patients with SAH and vasospasm was used both re-
ceptors were present and mediated the vasoconstriction; therefore combined blockade of both
receptors led to the maximal inhibition of the ET-1 induced contraction. The enhanced
endothelin contraction was absent in vessels without endothelium suggesting that an endothe-
lium-dependent mechanism contribute to the enhanced contractile endothelin-1 response ob-
served in arteries conditioned by CSF from SAH patients with vasospasm.
Upregulation of the endothelin system after incubation with CSF from
patients with vasospasm
In most functional studies on isolated vessels the two conditions of SAH, with and without va-
sospasm were not differentiated [6,9,10,12]. Only one study with human CSF clearly differenti-
ated the two SAH conditions but in that study the role of endothelin-1 was not investigated
[27]. The main novelty of the present study is the selection of human CSF with a definitive di-
agnosis of vasospasm established by angiography and integrated with TCD and clinical exami-
nation to investigate the endothelin-1 pathway in a model of isolated cerebral vessels.
Interestingly, we found that intact vessels incubated with CSF from SAH patients with vaso-
spasm resulted in a greater contractile response to ET-1 demonstrated by the left shift of the
Figure 3. Immunoreactivity of ET Receptors. Representative examples of rat basilar arteries showing immunoreactivity in the smooth muscle cell layer of
ETA (panel A) and ETB (panel B) following incubation with human 5%CSF fromControl (n = 9), Non-Vasospasm (n = 8) and Vasospasm patients (n = 9).
Negative controls for ETA and ETB antibodies were obtained excluding primary antibodies and in both cases resulted in no specific staining Pictures were
obtained using a × 40 objective.
doi:10.1371/journal.pone.0116456.g003
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concentration response curve with higher Emax and pEC50 (i.e. increased potency and sensitiv-
ity to ET-1) when compared to vessels incubated with CSF from non-vasospasm and control
patients. The increased sensitivity to ET-1 induced by organ culture was presumably present in
all our different experimental groups and therefore equally influenced all our results. In our
study cerebral arteries were incubated with Dulbecco medium containing 5% human CSF. Al-
though ET-1 was detectable in all CSF samples of the patients studied, we applied a dilution
factor which brought ET-1 concentrations below the detectable range in both groups. There-
fore, the amount of ET-1 measured in the culture medium was the result of the stimulation of
the arterial segments by CSF from the patients. The choice of CSF from day 4–5 for the present
study is explained by the fact that we verified that patients with severe angiographic vasospasm
on day 7 (clinical vasospasm) had a significant increase in MCA velocity on TCD on day 4–5
suggesting that molecular mechanisms responsible for vasospasm were already activated at
that time. Among the soluble factors derived from the blood, oxidative stress [28], increased
coagulation, fibrinolysis cascade, arachidonic acid metabolites and inflammatory mediators
[29] may be involved. Recently it has been suggested that SAH induces early activation of the
MEK-ERK1/2 pathway in cerebral artery walls, which is associated with upregulation of proin-
flammatory cytokines and MMP-9 [30].
The vessels incubated with CSF from patients with SAH and vasospasm had higher secreted
ET-1 levels suggesting that soluble factors present in the CSF of this group of patients were able
to trigger greater ET-1 secretion compared to CSF from patients without vasospasm. It is a lim-
itation that only CSF obtained at day 4–5 were examined, but on the other hand that was
where the vasospasm was most pronounced. Moreover, it would be an advantage if secretion
and “de novo” production of ET-1 could have been discriminated by measurements of
mRNA levels.
Table 3. Contractile response to ET-1 of intact rat basilar arteries following incubation with human CSF and ETA antagonist (BQ-123), ETB
antagonist (BQ-788) and combined ETA and ETB antagonists (BQ-123 and BQ-788).
Biphasic Curves Sigmoidal Curves
Emax1 ± SEM
(nN/mm)
Emax2 ± SEM
(nN/mm)
pEC50(1)±SEM pEC50(2)±SEM Emax ± SEM
(nN/mm)
pEC50 ± SEM
Ctrl Vehicle (n = 7) 0.79±0.26 1.52±1.18 13.13 ± 0.71 8.67 ± 0.54
BQ-123 (n = 8) 0.65 ± 0.07 14.57 ± 3.40
BQ-788 (n = 7) 2.17 ± 0.13 9.74 ± 0.19
BQ-123 + BQ-788 (n = 5) 0.26±0.08 7.67±0.52
NVS Vehicle (n = 8) 1.00 ± 0.09 1.65 ± 0.07 12.40 ± 0.29 9.35 ± 0.32
BQ-123 (n = 8) 0.53 ± 0.19† 1.56 ± 0.51 12.49 ± 0.62 7.39 ± 0.53†
BQ-788 (n = 8) 1.02 ± 0.08 2.06 ± 0.21 11.36 ± 0.35 8.79 ± 0.29
BQ-123 + BQ-788 (n = 5) 0.88±0.32 7.42±0.42
VS Vehicle (n = 9) 1.61 ± 0.32 * 2.29 ± 0.16* 13.03 ± 0.54 9.22 ± 0.64
BQ-123 (n = 9) 0.86 ± 0.43† 1.91 ± 0.82 12.81 ± 0.54 7.29 ± 0.78†
BQ-788 (n = 9) 1.16 ± 0.10† 2.17 ± 0.10 11.83 ± 0.33 9.16 ± 0.31
BQ-123 + BQ-788 (n = 5) 0.61±0.27 7.31±0.23
Responses were characterized by Emax and pEC50 values (negative logarithm of the molar concentration that produced half-maximum contraction). NVS =
non vasospasm, VS = vasospasm. Values are expressed as mean ± SEM. Significance was determined by a one-way ANOVA with a Tukey-Kramer post-
hoc analysis between CSF, where * p<0.05 = Vasospasm versus Control and Non-Vasospasm, and by a Student’s t-test between antagonists and
vehicle, where †p<0.05 = BQ-123 versus Vehicle.
doi:10.1371/journal.pone.0116456.t003
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Involvement of ETA and ETB receptors after incubation with CSF from
patients with vasospasm
In physiological conditions the biological effects of ET-1 are mediated through activation of
the two ET receptors: ETA which induces vasoconstriction on smooth muscle cells, whereas the
endothelial ETB mediates vasodilation [31]; consequently endothelium removal leads to the
abolishement of the vasodilator modulation. After SAH a different endothelium dependent ef-
fect of ET-1 may be expected and the upregulation of vascular smooth muscle ETB receptor
may contribute to vasoconstriction [32]. Indeed a functional interaction between ETA and ETB
also named “cross talk” has been recently proposed to explain the limited efficacy of selective
ET receptors antagonists [33].
Figure 4. Concentration-response curves for ET-1 after ETA (BQ-123), ETB (BQ-788) or both receptors
blockade on isolated rat basilar arteries following incubation with 5% CSF fromNon-Vasospasm
(panel A) and Vasospasm (panel B) patients. In theNon-Vasospasm group, the response to ET-1 was
significantly reduced by the ETA antagonist (n = 8), was not altered by the ETB (n = 8) antagonist and greatly
reduced by both antagonists (n = 5) compared to Vehicle (n = 8), whereas in the Vasospasm group, the
increased sensitivity to ET-1 was significantly reduced by the ETB (n = 9) antagonist in the low range, by the
ETA antagonist (n = 9) in the high range of ET-1 concentrations and was completely abolished by combined
receptors blockade (n = 5) compared to Vehicle (n = 9). Significance at each concentration by a two-way
ANOVA followed by a one-way ANOVA with Dunnett’s post-hoc analysis between groups, where *p<0.05 =
ETA antagonist versus vehicle, †p<0.05 = ETB antagonist versus vehicle, #p<0.05 = ETA and ETB
antagonists versus vehicle.
doi:10.1371/journal.pone.0116456.g004
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ETA receptors have previously been suggested as the main responsible for the pathogenesis
of vasospasm. Thus, after SAH, ETA receptor expression on smooth muscle cells was un-
changed but blockade of ETA receptor with clazosentan reduced the contraction to ET-1 [16].
Another two studies in SAH animal models showed upregulation of mRNA expression of the
ETA receptor after SAH [5,6]. In the present study, ETA receptors were expressed in the smooth
muscle layer of arteries exposed to CSF from all three groups of patients. These findings togeth-
er with the increased functional endothelin-1 response in arteries exposed to CSF from patients
with vasospasm suggest that antagonism of ETA receptors would be attractive. However, ETB
receptors have also been suggested to play a role in the pathogenesis of vasospasm [10,34,35].
In different models of SAH increased levels of ETB receptor mRNA with associated enhanced
functional response to ET-1 have been shown [8,11]; in a rat model of SAH, upregulation of
ETB receptor, specific functional response, and mRNA and protein expression were reported
[9]. Selective decrease in ETB receptor-dependent relaxation [36] and reduced vasospasm after
specific ETB receptor antagonist [17] have also been reported. In the present study, we found
that the ETB receptor was not constitutively expressed in smooth muscle cells in control condi-
tions and, more importantly, when using CSF from SAH patients without vasospasm but only
CSF from SAH patients with vasospasm induced an apparently marked expression of ETB re-
ceptors in the vascular smooth muscle cell layer.
Finally, we evaluated a) the functional response of intact vessels after selective and com-
bined blockade of ETA and ETB receptors and b) the functional response of intact and denuded
isolated vessels to CSF from SAH patients with and without vasospasm. In the non vasospasm
group, only selective ETA blockade induced a dose-dependent right shift of the concentration-
response curve. This is explained by the fact that ETA is constitutively expressed in control con-
ditions; the hemorrhagic event on its own does not cause upregulation of ETB receptors so that
ETB blockade had no effect. In the vasospasm group, both receptor types were upregulated.
ETB expression on smooth muscle cells was associated with increased tone and consequently
antagonism of both receptors induced a right shift of the ET-1 concentration-response curves:
the effect of ETB blockade was significant at low ET-1 concentrations (high affinity phase)
whereas the effect of ETA blockade was significant at high ET-1 concentrations (low affinity
phase). After blocking both receptors the increased tone was abolished throughout the ET-1
concentration range suggesting the involvement of both receptors in the enhanced contractile
response to ET-1. Furthermore the contractile response elicited by incubation with CSF from
patients with vasospasm was abolished in vessels without endothelium suggesting that the con-
dition of vasospasm after SAH induced an alteration in endothelial function contributing to
the enhanced tone. These results may be explained by 1) ET-1 secreted by endothelial cells in
the culture medium contributes to vasoconstriction [37]; 2) the existence of ETA receptor in
the spastic vessels [7]; 3) the dual “vasodilator-vasoconstrictor” role of ETB receptors as de-
scribed in pulmonary vessels [38,39]; 4) the heterodimerization of ET receptors described in
pulmonary hypertension [38]. The latter hypothesis may explain why combination of selective
ETA and ETB antagonists resulted in near maximal inhibition of ET-1
induced vasoconstriction.
Conclusion and Perspectives
What additional information does the present translational study provide after several clinical
trials [18–20,22,40] with endothelin receptor antagonists which showed reduction in angio-
graphic vasospasm but no improvement in measureable functional outcomes?
In a recent metanalysis Vergouwen et al [41] suggested that endothelin receptor antagonists
might be effective in selective subgroups of patients. In this perspective our data indeed suggest
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that only a well-defined subgroup of patients who develop severe vasospasm induced expres-
sion of both receptors mediating vasoconstriction and therefore specific targeting ETA recep-
tors was not sufficient to maximally inhibit vasospasm. The limited efficacy of selective ET
receptor antagonists may be due to the functional interaction between ETA and ETB receptors
named “cross talk”.
The “cross talk” between the two receptors can be functionally interpreted as a cooperative
inhibition by combined selective ET receptor blockade of the ET-1 induced contraction
[33,42]. In line with this hypothesis in the present study, only blockade of both receptors in-
duced an optimal reduction in the contractile response to ET-1.
In conclusion we studied the functional response, protein expression, and the effects of se-
lective and combined blockade of both receptors in two well-defined conditions: intact conduc-
tive cerebral vessels exposed to the biological effects of the hemorrhagic event (SAH without
vasospasm) and vessels exposed to the combined biological effects of SAH and vasospasm.
When CSF from patients with SAH and vasospasm was used both receptors were upregulated
and mediated vasoconstriction; therefore combined blockade of both receptors led to a maxi-
mal inhibition of ET-1-induced contraction. This enhanced ET-1 contraction was abolished in
vessels without endothelium suggesting that the condition of vasospasm after SAH induced an
alteration of endothelial function contributing to the enhanced tone. Further studies are re-
quired to demonstrate the exact nature of the functional interaction or “cross talk” between the
two receptors [33].
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